PDS Biotechnology Says Expands VERSATILE-002 Study Of PDS0101, KEYTRUDA In Advanced Head And Neck Cancer To Include Patients Who Have Failed Prior Treatment With Checkpoint Inhibitors
PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell
Stocks That Hit 52-Week Highs On Friday
Before 10 a.m. ET Friday, 188 stocks made new 52-week highs.
60 Biggest Movers From Yesterday
Gainers
Lizhi Inc. (NASDAQ: LIZI) shares surged 57.6% to close at $6.84 on Wednesday.
The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 24)
60 Biggest Movers From Yesterday
Gainers
Big Rock Partners Acquisition Corp. (NASDAQ: BRPA) shares jumped 88% to settle at $36.08 on Thursday.